U.S. patent application number 13/114878 was filed with the patent office on 2011-11-24 for method and apparatus for delivery of therapeutic agents.
This patent application is currently assigned to Ichor Medical Systems, Inc.. Invention is credited to Brady M. Bernard, Robert M. Bernard, Andrew W. Hannaman, Steven P. Masterson.
Application Number | 20110288467 13/114878 |
Document ID | / |
Family ID | 29248203 |
Filed Date | 2011-11-24 |
United States Patent
Application |
20110288467 |
Kind Code |
A1 |
Bernard; Robert M. ; et
al. |
November 24, 2011 |
METHOD AND APPARATUS FOR DELIVERY OF THERAPEUTIC AGENTS
Abstract
Methods and apparatus for the reproducible, consistent and
efficacious delivery of a therapeutic agent to a patient. The
invention includes controlled administration of the therapeutic
agent through an orifice to the patient, a plurality of penetrating
electrodes arranged with a predetermined spatial relationship
relative to the orifice, and an electrical signal generator
operatively connected to the electrodes.
Inventors: |
Bernard; Robert M.; (Rancho
Santa Fe, CA) ; Hannaman; Andrew W.; (San Diego,
CA) ; Bernard; Brady M.; (Seattle, WA) ;
Masterson; Steven P.; (Encinitas, CA) |
Assignee: |
Ichor Medical Systems, Inc.
San Diego
CA
|
Family ID: |
29248203 |
Appl. No.: |
13/114878 |
Filed: |
May 24, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10510399 |
May 26, 2005 |
|
|
|
PCT/US03/10337 |
Apr 4, 2003 |
|
|
|
13114878 |
|
|
|
|
Current U.S.
Class: |
604/20 |
Current CPC
Class: |
A61M 5/20 20130101; A61N
1/306 20130101; A61N 1/30 20130101; A61M 5/2053 20130101; A61M
2005/206 20130101; A61M 5/2033 20130101; A61M 5/46 20130101; A61M
5/30 20130101; A61M 5/326 20130101 |
Class at
Publication: |
604/20 |
International
Class: |
A61M 37/00 20060101
A61M037/00 |
Claims
1-20. (canceled)
21. An apparatus for the intracellular delivery of a therapeutic
agent to a predetermined site within the tissue of a patient
comprising: means for the administration of said therapeutic agent
to said patient comprising a reservoir for the therapeutic agent,
at least one orifice through which the agent is administered, and
an inanimate source of energy sufficient to transfer a
predetermined amount of the therapeutic agent from said reservoir
through said orifice to the predetermined site within the tissue of
the patient; a plurality of penetrating electrodes arranged with a
predetermined spatial relationship relative to said orifice; and
means configured for generating an electrical field which
facilitates the intracellular delivery of said therapeutic agent
said means operatively connected to said electrodes.
22. The apparatus as recited in claim 21 wherein the electrodes
comprise a subassembly that can be separated from the orifice.
23. The apparatus as recited in claim 21 further comprising means
for adjusting the predetermined spatial relationship between said
electrodes and said orifice.
24. The apparatus as recited in claim 23 wherein said means for
adjusting the spatial relationship comprises a source of
energy.
25. The apparatus as recited in claim 21 wherein the electrodes
comprise a conductive, electrochemically stable compound.
26. The apparatus as recited in claim 21 wherein the electrodes
comprise a conductive metal coated with a conductive,
electrochemically stable compound.
27. The apparatus as recited in claim 25 wherein said conductive,
electrochemically stable compound consists of at least one of the
following materials: titanium nitride, platinum, platinum iridium,
iridium oxide.
28. The apparatus as recited in claim 21 wherein the means for
administration of the therapeutic agent is a jet injector.
29. The apparatus as recited in claim 28 wherein the source of
energy to transfer the therapeutic agent is at least one compressed
gas.
30. The apparatus as recited in claim 28 wherein the source of
energy to transfer the therapeutic agent is at least one
spring.
31. The apparatus as recited in claim 28 wherein the jet injector
comprises means for controlling the rate at which the agent is
transferred through the orifice.
32. The apparatus as recited in claim 21 wherein the means for
administration of the therapeutic agent is an automatic injection
device.
33. The apparatus as recited in claim 32 wherein said reservoir is
a syringe including a penetrating hypodermic needle.
34. The apparatus as recited in claim 32 wherein the source of
energy to transfer the therapeutic agent is at least one compressed
gas.
35. The apparatus as recited in claim 32 wherein the source of
energy to transfer the therapeutic agent is at least one
spring.
36. The apparatus as recited in claim 33 wherein the automatic
injection device comprises means for controlling the depth of
penetration of said needle into the patient.
37. The apparatus as recited in claim 32 wherein the automatic
injection device comprises means for controlling the rate at which
the agent is transferred through the orifice.
38. The apparatus as recited in claim 26 wherein said conductive,
electrochemically stable compound consists of at least one of the
following materials: titanium nitride, platinum, platinum iridium,
iridium oxide.
39. The apparatus as recited in claim 21 wherein the means for
generating an electrical field is configured to induce an
electrical field of from approximately 50 to approximately 300 V/cm
between at least two of said electrodes.
40. The apparatus as recited in claim 21 wherein die means for
generating an electrical field is configured to deliver a signal
for a duration of from approximately 1 microsecond to approximately
100 milliseconds and at a frequency of from approximately 0.1 Hertz
to approximately 1 megahertz to at least two of said electrodes.
Description
TECHNICAL FIELD
[0001] The present invention is directed to the delivery of
prophylactic and therapeutic agents to patients and, more
particularly, to the reproducible, consistent, and efficacious
delivery of prophylactic and therapeutic agents, such as nucleic
acids, drugs, and proteins, to defined regions in selected tissues
of interest.
BACKGROUND OF THE INVENTION
[0002] Prophylactic and therapeutic agents have long been delivered
to patients using various conventional routes of administration,
such as topical, oral, intravenous, parenteral, and the like. Once
administered to the patient by the selected route, the delivery of
the agent to the tissue of interest and its beneficial interaction
with the tissue is largely dependent on its inherent
physicochemical factors, but may have been facilitated by, for
example, selected components of the delivery composition such as
carriers, adjuvants, buffers and excipients, and the like.
[0003] More recently, the application of electrical signals has
been shown to enhance the movement and uptake of macromolecules in
living tissue. Application of such electrical signals in tissue
relative to the administration of a prophylactic or therapeutic
agent can have desirable effects on the tissue and/or the agent to
be delivered. Specifically, techniques such as electroporation and
iontophoresis have been utilized to significantly improve the
delivery and/or uptake of a variety of agents in tissue. Such
agents include pharmaceuticals, proteins, and nucleic acids.
Potential clinical applications of such techniques include the
delivery of chemotherapeutic drugs and/or therapeutic genes in
tumors, the delivery of DNA vaccines for prophylactic and
therapeutic immunization, and the delivery of nucleic acid
sequences encoding therapeutic proteins.
[0004] Many devices have been described for the application of
electrical signals in tissue for the purpose of enhancing agent
delivery. The vast majority of these have focused on a means for
effective application of the electrical signals within a target
region of tissue. A variety of surface and penetrating electrode
systems have been developed for generating the desired
electrophysiological effects.
[0005] In spite of the promise associated with electrically
mediated agent delivery and the potential clinical applications of
these techniques, progress has been hampered by the lack of an
effective means to achieve the overall objective of efficient and
reliable agent delivery using these techniques. One of the most
significant shortcomings of current systems is the inability to
achieve reliable and consistent application from subject to
subject. Significant sources of this variability are due to
differences in the technique and skill level of the operator. Other
sources of variability that are not addressed by current systems
include differences in the physiologic characteristics between
patients that can affect the application of the procedure.
[0006] Given that reliable and consistent application of clinical
therapies is highly desirable, the development of improved
application systems is well warranted. Such development should
include a means for minimizing operator-associated variability
while providing a means to accommodate the differences in patient
characteristics likely to be encountered during widespread clinical
application of electrically mediated agent delivery.
DISCLOSURE OF THE INVENTION
[0007] The present invention provides improved methods and
apparatus for the reproducible, consistent, and efficacious
delivery of therapeutic agents, such as nucleic acids, drugs, and
proteins, to patients utilizing Electrically Mediated Therapeutic
Agent Delivery.
[0008] In one aspect, the present invention provides an apparatus
for the delivery of a therapeutic agent to a predetermined site
within a patient comprising means for the controlled administration
of the therapeutic agent to the patient comprising a reservoir for
the therapeutic agent, at least one orifice through which the agent
is administered, and a controlled source of energy sufficient to
transfer a predetermined amount of the therapeutic agent at a
predetermined rate from the reservoir through the orifice to the
predetermined site within the patient. In addition, the apparatus
comprises a plurality of penetrating electrodes arranged with a
predetermined spatial relationship relative to the orifice, and
means for generating an electrical signal operatively connected to
the electrodes.
[0009] Other aspects of the invention include methods comprising
Therapeutic Agent Administration in controlled spatial and temporal
conjunction with Electric Signal Administration.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] FIGS. 1A-C are graphic depictions of potential sources of
spatial variability associated with conventional needle syringe
injection;
[0011] FIG. 2 is a cross sectional depiction of an embodiment of an
apparatus of the invention comprising an integrated means for
therapeutic agent administration and electrical signal
application;
[0012] FIG. 3 is a cross sectional depiction of an alternative
embodiment of an apparatus of the invention comprising an
integrated means for therapeutic agent administration and
electrical signal application;
[0013] FIG. 4A is a cross sectional view of a portion of an
embodiment of the invention during therapeutic agent
administration;
[0014] FIG. 4B is a bottom view of the embodiment of FIG. 4A,
depicting the portion of the apparatus which interfaces with the
tissue of a patient;
[0015] FIGS. 5A-D illustrate several embodiments of embodiments of
the invention depicting the portion of the apparatus that
interfaces with the tissue of a patient;
[0016] FIG. 6A is a partial cross sectional view of a further
alternative embodiment of an apparatus of the invention comprising
an integrated means for therapeutic agent administration and
electrical signal application;
[0017] FIG. 6B is a bottom plan view of the embodiment of FIG. 6A,
depicting the portion of the apparatus which interfaces with the
tissue of a patient;
[0018] FIG. 7 is a block diagram of a treatment system in
accordance with the invention.
[0019] FIG. 8 A illustrates a specific integrated unit embodiment
comprising a main unit and a separable sub-assembly;
[0020] FIG. 8 B is a view of the specific embodiment depicting the
sub-assembly attached to the main unit;
[0021] FIG. 9 A is a side view of the separable sub-assembly of the
specific embodiment of FIG. 8;
[0022] FIG. 9 B is a cross-sectional view of the separable
sub-assembly depicted in FIG. 9A;
[0023] FIG. 9 C is a bottom plan view of the embodiment of FIGS. 9A
and 9B, depicting the portion of the apparatus which interfaces
with the tissue of a patient;
[0024] FIG. 10 A illustrates the main unit of the specific
embodiment of FIG. 8:
[0025] FIG. 10 B is a cross-sectional view of the main unit
depicted in FIG. 10A;
[0026] FIGS. 11 A-D are sequential cross-sectional views depicting
selected steps comprising the treatment sequence utilizing the
specific embodiment of FIG. 8, in which
[0027] FIG. 11A depicts the apparatus as it is brought into contact
with the skin of a patient and the shield has retracted into the
body of the sub-assembly,
[0028] FIG. 11B depicts the apparatus as it is activated and the
electrode array and syringe needle have penetrated the skin of the
patient,
[0029] FIG. 11C depicts the apparatus in the next phase of
activation where the agent of interest has been distributed into
the predetermined area of interest, and
[0030] FIG. 11D depicts the apparatus after it is withdrawn from
the skin of the patient and the shield has extended to encompass
the syringe needle and electrode array; and
[0031] FIG. 12 is a cross-sectional view of the specific embodiment
of FIG. 8 depicting the electrical connection between the
electrodes and the main unit.
DETAILED DESCRIPTION OF THE INVENTION
[0032] The present invention provides improved methods and
apparatus for the reproducible, consistent, and efficacious
delivery of therapeutic agents, such as nucleic acids, drugs, and
proteins, with Electrically Mediated Therapeutic Agent Delivery
(EMTAD).
[0033] In one aspect, the present invention provides an apparatus
for the delivery of a therapeutic agent to a predetermined site
within a patient comprising means for the controlled administration
of the therapeutic agent to the patient comprising a reservoir for
the therapeutic agent, at least one orifice through which the agent
is administered, and a controlled source of energy sufficient to
transfer a predetermined amount of the therapeutic agent at a
predetermined rate from the reservoir through the orifice to the
predetermined site within the patient. In addition, the apparatus
comprises a plurality of penetrating electrodes arranged with a
predetermined spatial relationship relative to the orifice, and
means for generating an electrical signal operatively connected to
the electrodes.
[0034] In the present invention, EMTAD is defined as the
application of electrical signals to biological tissue for the
purpose of enhancing movement and/or uptake of a therapeutic agent
in tissue. The process of EMTAD is comprised of two elements: 1)
Therapeutic Agent Administration (TAA), and 2) an Electrical Signal
Application (ESA) sufficient to induce the desired EMTAD effect. In
the present invention, therapeutic agent administration is
accomplished in a controllable fashion, termed Controlled
Therapeutic Agent Administration (CTAA). The term CTAA used herein
refers to methods and apparatus capable of providing spatial and
temporal control over administration of a therapeutic agent
relative to the induction of an EMTAD effect. Controllable
administration techniques may utilize variations on the
conventional needle-syringe (e.g. automatic injection device)
and/or various needleless methodologies (e.g. jet injector,
transdermal/transcutaneous patch, oral, gel, cream, or inhaled
administration). The term ESA used herein refers to the application
of electrical signals to facilitate or enhance the delivery of
therapeutic agents by improving movement and/or uptake of said
agents within tissue, thus inducing an EMTAD effect. When used to
facilitate or enhance delivery of a therapeutic agent, ESA
processes such as electroporation, iontophoresis, electroosmosis,
electropermeabilization, electrostimulation, electromigration, and
electroconvection all represent various modes of EMTAD.
[0035] Specific applications for EMTAD include, but are not limited
to, the delivery of vaccines, therapeutic proteins, and
chemotherapeutic drugs. Traditionally with such applications, EMTAD
is initiated by therapeutic agent injection using a conventional
needle-syringe. After the agent has been administered, a device
suitable for ESA is applied to the patient at a designated
location. Finally, an appropriate ESA protocol is utilized to
provide the desired facilitation or enhancement to therapeutic
agent delivery. With traditional EMTAD, however, the desired
spatial and temporal relationship between agent administration and
ESA may not be realized.
Spatial Parameters
[0036] For agents in which the use of EMTAD is not required or
desirable, therapeutic agent administration is often performed
using a conventional needle syringe. While the therapeutic
objectives can usually be accomplished using these means, the need
to deliver certain agents with EMTAD brings an additional level of
complexity to the issue of TAA. As depicted in FIG. 1, in any
conventional needle-syringe injection, as the needle 5 is inserted
into the tissue, the depth 1 and the angle 2 of insertion relative
to the surface of the tissue 3 can be difficult to control.
Additionally, the point of needle penetration 4 at the tissue
surface 3 may not be representative of the location of the orifice
6 and the region of agent administration 7 within the target
tissue. As an illustrative example a transcutaneous intramuscular
injection may not correspond to the site of insertion on the skin
since the two tissues can often move in relation to one
another.
[0037] While this conventional approach is generally adequate for
the delivery of many different therapeutics that do not require
EMTAD, these variables lead to a distribution of the therapeutic
agent following injection that is often inconsistent and/or
indeterminate and can hamper effective EMTAD. Commonly, the most
effective use of EMTAD utilizes a predefined relationship between
the therapeutic agent and ESA within the patient. As a result, the
lack of spatial control over TAA in a target tissue using a
conventional needle syringe can hamper the outcome of the EMTAD
application. One illustrative example of this concept is the use of
electroporation to facilitate the delivery of a therapeutic agent.
Electroporation is typically most effective in enhancing
therapeutic agent delivery when TAA and ESA are co-localized within
the target region of tissue. In many cases, if the agent to be
delivered and the induced electroporation effect are not
co-localized within the target region of tissue, the delivery of
said agent is suboptimal.
[0038] Another example of the need for adequate spatial control of
TAA in EMTAD is iontophoresis. This mode of EMTAD uses electrical
fields to cause movement of charged molecules. In order to achieve
the desired movement of the agent, the proper spatial relationship
between the electrodes and the therapeutic agent must be realized.
If a negatively charged agent were placed in close proximity to the
location of a positive electrode, little or no movement of the
agent through the tissue would be observed. In contrast,
localization of the said negatively charged agent near the negative
electrode would result in significant movement of the agent through
the tissue in the direction of the positive electrode.
[0039] As illustrated by the preceding examples, care must be taken
to control the precise location of TAA relative to the application
of ESA to achieve the desired effect. As a result, methods for
achieving reproducible, consistent, and well-characterized
distribution of the therapeutic agents are highly desirable.
Temporal Parameters
[0040] Another disadvantage with conventional needle-syringe
injection TAA is that the rate of injection may vary from one
operator to another, thereby causing inconsistent agent
distribution in the tissue. Additional temporal variability is
introduced when multiple apparatus placements are required to
complete the EMTAD process. For example, one application of EMTAD
calls for the administration of plasmid DNA encoding for a
therapeutic protein, followed by generation of an
electroporation-inducing electrical field. Using the traditional
method of EMTAD, the plasmid is injected with a needle-syringe,
followed by placement and activation of the electroporation
apparatus. By requiring two separate apparatus placements (the
initial needle syringe followed by the ESA apparatus), this
procedure is susceptible to inter-patient variability arising from
inconsistent temporal application of each apparatus by the
operator. Additionally, the use of two separate apparatus
placements leads to an unavoidable time interval in between the
clinician's placement and activation of each apparatus. This is
compounded in the case where multiple application sites are
necessary to achieve adequate delivery of the agent to a
specifiable region within the target tissue.
[0041] These issues are especially critical for agents, such as
nucleic acids, that can be degraded or inactivated in the
extracellular environment. Therapeutic agent degradation can lead
to a reduction in efficacy and consistency in the application of
the therapy. Also, the inter-patient rate of therapeutic agent
degradation is not constant, thus contributing to the overall
therapeutic inconsistency of conventional needle-syringe injection
combined with ESA, and more specifically with electroporation
therapy.
[0042] Due to the inherent difficulty of spatial and temporal
variability with conventional needle-syringe injection used in
conjunction with ESA, the precise location and timing of TAA
relative to ESA is often unknown. As a result, the effective
administration and dosing of therapeutic agents with EMTAD may be
inconsistent and irreproducible. Though conventional needle-syringe
injection is sometimes adequate for therapeutic agent
administration, reproducible and consistent agent delivery is
significantly enhanced by controlling the spatial and temporal
relationship between administration of the therapeutic agent and
induction of the desired EMTAD effect.
[0043] Thus, while the traditional EMTAD procedure may be adequate
for certain applications, temporal and spatial control is highly
desirable for clinical applications that typically require a high
degree of consistency and reproducibility. In contrast to the
conventional EMTAD approach previously described, several
techniques for combined CTAA and ESA are described herein to
provide more advantageous methods and apparatus for the clinical
application of EMTAD. The present invention utilizes various
aspects of CTAA in conjunction with ESA to provide reproducible,
consistent, and efficacious therapeutic agent delivery. More
specifically, this invention describes methods and apparatus to
provide spatial and temporal control over administration of a
therapeutic agent relative to the application of electrical
signals, thereby improving the movement and/or uptake of said agent
in the target tissue.
[0044] In the present invention, there exists a controllable
spatial relationship for the administration of the therapeutic
agent relative to the application of electrical signals. Prior to
treatment, the optimal location for TAA relative to ESA is
determined. This spatial relationship between TAA and ESA is
dictated by treatment parameters, including the nature of the agent
being administered and the properties of the target tissue to which
the agent is administered. In certain applications, electrical
signals are preferentially applied distal to the site of
therapeutic agent administration. However, the typical spatial
relationship is to apply the EMTAD-inducing electrical signals
proximal to the site of agent administration. In the practice of
such applications, co-localization between TAA and ESA may be
preferential. This is often the case when electroporation and/or
iontophoresis are utilized for induction of the desired EMTAD
effect.
[0045] Another aspect of the invention provides a controllable
temporal relationship for the sequence and timing of TAA relative
to ESA. Prior to treatment, the optimal sequence and timing for
combination of TAA and ESA is determined. As with the spatial
relationship, the desired temporal relationship between TAA and ESA
is dictated by parameters such as the nature of the agent being
administered and the properties of the target tissue to which the
agent is administered. In certain applications, exposure to the
electrical fields associated with ESA may adversely affect the
therapeutic agent. In the practice of such applications, generation
of such electrical fields is followed by CTAA. However, the typical
temporal relationship is CTAA followed by ESA.
[0046] The present invention provides improved methods and
apparatus for the reproducible, consistent, and efficacious
delivery of therapeutic agents, such as nucleic acid based
constructs, pharmaceutical compounds, drugs, and proteins, with
EMTAD. This objective is accomplished by controlling the spatial
and temporal administration of a therapeutic agent relative to
application of electrical signals. Specific applications for EMTAD
include, but are not limited to, the delivery of vaccines,
therapeutic proteins, and chemotherapeutic drugs. Traditionally
with such applications, EMTAD is initiated by therapeutic agent
injection using a conventional needle-syringe. After the agent has
been administered, an apparatus suitable for ESA is applied to the
patient at a designated location. Finally, an appropriate ESA
protocol is utilized to provide the desired facilitation or
enhancement to therapeutic agent delivery. One such ESA method that
has proven to be effective in virtually all cell types is
electroporation. Other methods of electrically mediated delivery
include iontophoresis, electroosmosis, electropermeabilization,
electrostimulation, electromigration, and electroconvection. These
terms are used for illustrative purposes only and should not be
construed as limitations in the invention.
[0047] The technique of electroporation utilizes the application of
electric fields to induce a transient increase in cell membrane
permeability and to move charged particles. By permeabilizing the
cell membranes within the target tissue, electroporation
dramatically improves the intracellular uptake of exogenous
substances that have been administered to the target tissue. The
increase in cell membrane permeability and molecular movement due
to electroporation offers a method for overcoming the cell membrane
as a barrier to therapeutic agent delivery. The application of
electroporation as a technique for inducing EMTAD is advantageous
in that the physical nature of the technique allows electroporation
to be applied in virtually all tissue types. Accordingly, all
aspects and embodiments of the invention discuss, but are not
limited to, electroporation as a technique for inducing EMTAD.
Therapeutic Agents
[0048] The term "therapeutic agent" will be used in its broadest
sense to include any agent capable of providing a desired or
beneficial effect on living tissue. Thus, the term will include
both prophylactic and therapeutic agents, as well as any other
category of agent having such desired effects. Clearly, the scope
of the present invention is sufficiently broad to include the
controlled delivery of any agent, however categorized. Therapeutic
agents include, but are not limited to pharmaceutical drugs and
vaccines, and nucleic acid sequences (such as supercoiled, relaxed,
and linear plasmid DNA, antisense constructs, artificial
chromosomes, or any other nucleic acid-based therapeutic), and any
formulations thereof. Such agent formulations include, but are not
limited to, cationic lipids, cationic polymers, liposomes, saline,
nuclease inhibitors, anesthetics, poloxamers, preservatives, sodium
phosphate solutions, or other compounds that can improve the
administration, stability, and/or effect of the therapeutic agent.
Additional benefits derived from certain agent formulations include
the ability to control viscosity and electrical impedance of the
administered agent, an important consideration for EMTAD
applications.
[0049] In the case of nucleic acids, an example of a therapeutic
agent would be plasmid DNA dissolved in a sodium phosphate solution
with a competitive nuclease inhibitor such as aurintricarboxylic
acid (ATA) added to the agent. In some embodiments using nucleic
acid-based therapeutics, it may also be advantageous to incorporate
a signaling peptide onto the construct. Potentially useful peptides
include, but are not limited to, nuclear localization signals,
endosomal lytic peptides, and transcriptional control elements.
These signals can enable improved delivery and/or processing of the
therapeutic agents delivered to the cells via EMTAD. This signaling
can be accomplished through the use of methods as described in U.S.
Pat. No. 6,165,720. While these techniques can be utilized with
other delivery systems, the ability of EMTAD to increase the
delivery of nucleic acid constructs to target tissues makes it
particularly well suited for use with such signals.
Target Tissues
[0050] Target tissues well suited for EMTAD include both healthy
and diseased cells located in the epidermis, dermis, hypodermis,
connective, and muscle tissue. The technique can also be utilized
for application in healthy or diseased organs that must be accessed
via minimally invasive or other surgical means. Such target tissues
include the liver, lungs, heart, blood vessels, lymphatic, brain,
kidneys, pancreas, stomach, intestines, colon, bladder, and
reproductive organs. One should note that the desired therapeutic
effect may be derived from agent delivery to cell types normally
located within the target tissues as well as other cell types
abnormally found within said tissues (e.g. chemotherapeutic
treatment of tumors).
[0051] As discussed previously, and depicted in FIG. 1, traditional
EMTAD suffers from a lack of precision and reproducibility in the
spatial and temporal relationship between the administration of the
therapeutic agent and the electrical signal. In contrast to the
traditional EMTAD approach, the present invention describes methods
and apparatus for combined CTAA and ESA to provide a more
advantageous clinical application of EMTAD. This invention utilizes
various aspects of CTAA in conjunction with ESA to provide
reproducible, consistent, and efficacious therapeutic agent
delivery. More specifically, the methods and apparatus proposed
herein provide spatial and temporal control over administration of
a therapeutic agent relative to the application of electrical
signals, thereby improving the movement and/or uptake of said agent
in the target tissue.
Methods
[0052] In one aspect, the invention described herein provides
methods for controlled administration of a therapeutic agent
followed by ESA. These methods consist of, but are not limited in
scope or sequential relationship to, the determination of treatment
parameters, patient preparation procedures, CTAA, ESA, and
additional measures.
Determination of Treatment Parameters
[0053] Treatment parameters are dictated by the desired dosing of
the therapeutic agent. Therapeutic agent dosing may depend on the
particular indication or treatment application (such as the type
and location of the target tissue), as well as various patient
parameters (such as age and body mass). Dosing of the therapeutic
agent may be controlled by parameters pertaining to administration
of the therapeutic agent and ESA. Controllable parameters
pertaining to CTAA include agent volume, agent viscosity, and
injection rate. Controllable parameters pertaining to ESA include
the characteristics of the electrical signals, the tissue volume
exposed to the electrical signals and the electrode array format.
The relative timing and location of CTAA and ESA are parameters
providing further control over therapeutic agent dosing.
Patient Preparation
[0054] Patient preparation includes, but is not limited to,
antiseptic cleansing and anesthetic administration, including local
or regional, nerve block, spinal block, epidural block, or general
anesthesia. In the case of intramuscular (IM) ESA, protocols to
minimize the effects of electrical stimulation of the muscle may be
taken, including thermal control (e.g. cooling the muscle),
administration of anesthetics, and/or alternative stimulation
patterns sufficient for mitigation of discomfort. One should ensure
that the selected patient preparation techniques do not adversely
affect therapeutic efficacy, if acceptable alternatives exist. For
example, it has been shown that certain anesthetics can have an
undesirable effect on plasmid DNA-based therapies.
CTAA and ESA
[0055] In the practice of the method, the application of CTAA and
ESA are combined, enabling consistent and reproducible therapeutic
agent delivery. Two representative embodiments of apparatus
suitable for CTAA include automatic injection apparatuses and jet
injectors.
CTAA Apparatus Embodiments
[0056] Turning now to the additional drawings, where like elements
are identified by like numerals throughout the figures, as depicted
in FIG. 2, in certain embodiments an automatic injection apparatus
10 is utilized as the means of controlled administration of
therapeutic agents to the target tissue. As used herein, an
automatic injection apparatus is an apparatus that is capable of
administering a therapeutic agent to a patient at a controlled rate
through at least one hollow injection needle 12, such as a
hypodermic needle, each with at least one orifice 14.
[0057] Conveniently, the automatic injection apparatus 10 will
utilize a housing 16 to enclose, for example, a conventional
disposable syringe 18, plunger 20 and needle 12 device, together
with the means necessary to insert the needle into the patient and
dispense the therapeutic agent through the needle (as described
below). Administration of therapeutic agents with automatic
injection apparatus 10 is initiated by an operator activating
trigger 22 and begins with the insertion of injection needle 12
containing one or more orifices 14 through which the therapeutic
agent can be transferred into the patient. Descriptions and
examples of automatic injection apparatuses which can find use in
the present invention are provided in U.S. Pat. Nos. 6,077,247 and
6,159,181, the entire disclosures of which are incorporated by this
reference.
[0058] Preferably, injection needle 12 is inserted into the patient
by a drive mechanism 24 contained within automatic injection
apparatus 10. Preferably, injection apparatus 10 also includes
depth control means 26 for reliably controlling the depth of
penetration of injection needle 12. Once needle 12 is inserted, the
therapeutic agent is transferred at a controlled rate from a
suitable reservoir 28 through orifice 14 of needle 12 and into the
patient. It is also considered desirable to include a means to
inhibit relative motion between the plunger and the body of the
syringe until such time as the injection needle has reached the
predetermined location within the patient, and thereby minimize the
distribution of the agent outside of the predetermined area of
interest.
[0059] The automatic injection apparatus 10 may contain a single
injection needle 12 or multiple needles, through which single or
multiple types of agents may pass, depending upon the specific
application. The energy source 30 utilized to transfer the
therapeutic agent from the reservoir 28 into the patient is
commonly compressed gas or a spring, though other sources may be
utilized.
[0060] Given that multiple applications for the present invention
are contemplated and that there are significant differences in body
and tissue composition between patients, it is likely that
reproducible and consistent practice of the invention in a large
patient population will desirably include a means for adjusting the
injection parameters. Such injection parameters include the needle
size, injectant viscosity, injectant volume, concentration of
therapeutics, and injection rate. A means for adjusting these
parameters is desirable to compensate for various characteristics
of the therapy recipient, including age, weight, dosing, target
tissue type, and the target tissue depth, especially for
transcutaneous administration (which may be affected, among other
factors, by the recipient's age and level of obesity).
[0061] In certain indications, a single-use and/or self-destructing
needle-syringe may be used as therapeutic agent reservoir 28,
thereby preventing cross-contamination of blood-borne pathogens
between recipients. Similarly, protection is provided to the
operator against accidental needle-stick injuries and resulting
blood-borne pathogen transmission by using automatic injection
apparatuses that incorporate a means of needle retraction 32 after
use. This method of agent administration is particularly useful in
high-risk situations, such as injecting patients infected with HIV,
Hepatitis, or any other blood-borne pathogens.
[0062] In one specific application of such an embodiment, an
automatic injection apparatus is used for IM injection of plasmid
DNA encoding for a therapeutic protein. Skeletal muscle has several
characteristics that make it a desirable target tissue for this
application. First, skeletal muscle constitutes up to 40% of the
average adult's body mass and is easily accessible for
transcutaneous administration of the plasmid. In addition, muscle
cells rarely divide in vivo and thus, the introduced plasmid will
not be lost during mitosis. Muscle cells are also multi-nucleated,
thereby providing multiple targets for the plasmid once it reaches
the intracellular space. These characteristics enable prolonged
expression and secretion of the protein into systemic circulation.
If the gene of interest can be transfected into an adequate number
of muscle fibers, the tissue can produce the protein at levels
sufficient to induce a biologic effect in patients. For example, an
anemic patient may receive an IM injection of plasmid DNA encoding
for the protein erythropoietin (EPO), followed by electroporation.
Upon treatment, transfected cells would produce and secrete the EPO
protein, leading to an increase in hematocrit. The benefits of
having such a treatment, which allows the body to manufacture its
own EPO, are very enticing. By introducing and expressing EPO in
muscle using electroporation, the body would be able to produce EPO
for an extended period of time and patients may require boosters at
substantially reduced time intervals.
[0063] In other embodiments of the present apparatus, as depicted
in FIGS. 3 and 4, a jet injector 100 is utilized as the means for
CTAA to the target tissue. Examples of jet injection devices
include: WIPO Publication Nos. WO0113975, WO0113977, and WO0009186.
Similar to the use of an automatic injection apparatus,
administration of therapeutic agents with a jet injector 100 is
initiated by an operator activating trigger 22 but transmission of
the agent from a jet injector to the patient relies on the
penetration of a high-pressure stream 102 of such agent through an
orifice 104 into the tissue. Although jet injection is typically
accomplished without the use of a penetrating injection needle, in
some cases the injection orifice 104 is located at the terminal end
of a mini-needle used to bypass the outermost layers of a tissue
system. The high-pressure stream 102 of therapeutic agent generated
by jet injector 100 then follows the path of least resistance as it
is forced through the tissue, resulting in a widely dispersed
distribution of the therapeutic agent (see FIG. 4A). The jet
injector 100 may contain a single orifice 104 or multiple orifices
for injection, through which single or multiple types of agents may
be transferred, depending upon the specific application. The source
of energy 30 used to activate a plunger 106 to transfer the
therapeutic agent from a suitable reservoir 28 through the
injection orifice 104 is commonly compressed gas or a spring, but
other energy sources can also be used.
[0064] In order to achieve reproducible and consistent agent
administration, where the population is expected to exhibit
variable patient parameters, the orifice size and shape, injectant
pressure, injectant viscosity, injectant volume, concentration of
therapeutics, and injection rate are a few examples of the
adjustable jet injection parameters which can be controlled. Such
adjustable parameters of the jet injector are necessary to account
for various characteristics of the therapy recipient, including
age, weight, dosing, target tissue type, and the target tissue
depth, especially for transcutaneous administration (which may be
affected, among other factors, by the recipient's age and level of
obesity). Such adjustable parameters may also be necessary to
ensure that the agent is stable and viable when exposed to the
pressure and shearing stress inherent to jet injection-mediated
administration.
[0065] In the case of transcutaneous injection, the interface
between the injector orifice and skin is also critical in achieving
reproducible and safe administration; the spatial location of the
jet injector should be maintained for the duration of injection. To
address this issue, in certain embodiments the jet injector can be
provided with the means of maintaining a slight vacuum 108 at the
apparatus/tissue interface to facilitate administration of the
technique and stabilize the spatial location of the unit. Interface
stabilization may also be accomplished with the use of adhesives,
with the temporary application of restraint mechanisms, or any
combination thereof.
[0066] A significant concern with jet injection technology is
ballistic contamination, in which the jet injection builds pressure
in the tissue that is greater than the pressure in the injector,
causing a small backflow of blood or other bodily fluids onto the
apparatus. In response to this problem, a single-use,
self-destructing vial 110 may be used for therapeutic agent
containment of the jet injector. This prevents cross-contamination
of blood-borne pathogens between recipients. Similarly, since most
jet injectors have no needle, protection is provided to the
operator against accidental needle-stick injuries and resulting
blood-borne pathogen transmission. Such a form of needleless
injection is particularly useful in high-risk situations, such as
injecting patients infected with HIV, Hepatitis, or any other
blood-borne pathogens.
ESA Parameters
[0067] One representative form of ESA is electroporation, but all
forms of ESA share certain common features desirable for the
efficient application of the techniques to EMTAD. A critical aspect
of electroporation is the generation and propagation of
electroporation-inducing electrical fields within the region of
tissue targeted for therapeutic agent delivery. There are several
methods for generating such fields in vivo, including surface and
penetrating electrode arrays. The present invention can be
practiced with any electrode system suitable for propagating the
electrical signals within the targeted region of tissue. The
specific characteristics of the electrode systems will determine if
that type of electrode is suitable for use in a given
application.
[0068] With surface style electrode arrays, an electrical field is
propagated through the surface of the skin and into the target
tissue. Unfortunately, surface style electrode arrays, such as
plates or meander-type electrodes (as described in U.S. Pat. No.
5,968,006), are inefficient or impractical for most indications.
The electrodes are typically unable to target regions beyond the
most superficial tissues, they cannot be applied in a reliable
fashion, and their use often can result in burning and scarring at
the site of application.
[0069] Penetrating electrodes are typically more desirable for ESA.
Penetrating electrodes are defined as conductive elements whose
size and shape are sufficient to enable insertion through the
matter covering a tissue of interest, such as skin covering muscle
tissue, or the outer layer(s) of such tissue. There are numerous
embodiments of penetrating electrode array systems, including
bipolar and multielement electrode arrays. The simplest penetrating
electrode array is the bipolar system, which consists of two
penetrating electrodes connected to the opposite poles of a pulse
generator. Systems of penetrating bipolar electrodes have been used
extensively in preclinical studies of electroporation. However, the
non-uniform electrical fields characteristic of bipolar electrodes
makes them an inefficient means for generating threshold levels
sufficient for electroporation throughout a target region of
tissue. More complex systems have been developed using three or
more electrodes to comprise a multielement array. The specific
geometrical arrangement and activation pattern of these
multi-element arrays can result in superior performance
characteristics compared to the bipolar approach.
[0070] For many clinical indications, a grid-based multi-element
electrode array, such as the TriGrid.TM. electrode system, is the
most advantageous means of applying ESA in accomplishing the
therapeutic objective. The TriGrid.TM. system, disclosed in U.S.
Pat. No. 5,873,849 (the entire disclosure of which is incorporated
herein by reference), consists of slender penetrating electrodes
with a geometry and activation pattern designed to maximize field
uniformity within a targeted volume of tissue. As a result, the
electroporation effect can be achieved throughout the target volume
with minimized variability due to the electrical fields propagated
within the tissue.
[0071] The TriGrid.TM. design considerations ensure that the
threshold field strengths required to achieve electroporation are
propagated throughout the target tissue while minimizing the amount
of tissue exposed to excessively high fields that could result in
tissue injury. These more uniform electric field distributions are
achieved by simultaneously activating more than two of the
electrodes within the array, thereby reinforcing the electric
fields being propagated in the more central tissues away from the
electrodes. Since the probability of achieving membrane
permeability can also depend on the physical dimensions and
orientation of the cell, the sequential propagation of electrical
fields at different angles increases the likelihood that the
electroporation effect can be achieved in any given cell.
[0072] As depicted in FIG. 5, each set of four electrodes
establishing a generally diamond shaped multi-element array is
called a Unit TriGrid.TM. 50. Any number of Unit TriGrid.TM.
"modules" can be integrated together and expanded to form electrode
arrays with different geometries capable of treating various shapes
and volumes of tissue. Several important clinical benefits are
derived from the use of the expandable TriGrid.TM. electrode array
system. First, the system allows the patient to be treated with a
single placement of the electrodes, thereby minimizing the time
required for the procedure and reducing any discomfort associated
with repeated penetration and stimulation of an electrode array.
Second, by controlling the amount of tissue exposed to the
electroporation fields, the grid based electrode format essentially
provides a method for accurately adjusting the dose of the
therapeutic agent. Finally the TriGrid.TM. is likely to result in
consistent application of the treatment from patient-to-patient and
operator-to-operator since it reduces uncertainty associated with
the amount of tissue targeted by threshold level
electroporation-inducing electrical fields.
[0073] In certain preferred embodiments, a TriGrid.TM. array is
utilized as the mode of establishing electroporation-inducing
electrical fields. A high voltage electrical state sequencer and
electrical signal generator is connected to each of the electrodes
through conductive cables, thus generating an
electroporation-inducing electrical field. In order to achieve
reproducible and consistent therapeutic efficacy provided variable
patient parameters, the electrode size, shape, and surface area,
the electrical field strength (typically 50-2000 volts per
centimeter), the frequency of stimulation (typically 0.1 Hertz to 1
megahertz), the waveform (such as bipolar, monopolar, AC,
capacitive discharge, square, sawtooth, or any combination thereof)
and the electrical signal duration (typically 1 microsecond to 100
milliseconds) are a few examples of the adjustable
electroporation-inducing electrical field parameters. Selection of
such adjustable electroporation parameters is based, among other
factors, on the agent to be delivered, the dosing, the specific
application and method of administration, the type and location of
the target tissue, and the volume to be treated. In other
embodiments, plate electrodes, bipolar, and other multielement
electrode arrays may be utilized as the mode of generating
electroporation-inducing electrical fields; however, the
TriGrid.TM. array is superior in accomplishing the therapeutic
objective for most indications.
Additional Procedures
[0074] There are several additional procedures that may be included
in the application of CTAA and ESA, which assist in the
accomplishment of the desired therapeutic objective. For instance,
after the therapeutic agent has been administered it may be
advantageous to utilize techniques to enhance agent distribution
within the tissue by molecular movement. Suitable techniques to
enhance molecular movement and homogeneity include iontophoresis,
electroosmosis, ultrasound, and thermal means. In the case of
iontophoresis and electroosmosis, it may be desirable to use the
same electrodes that deliver electroporation; however, additional
electrodes may be used. The administration of dexamethasone and
poloxamer, among other agents that can affect the state of the cell
membrane, have been shown to enhance various aspects of
electroporation therapy. Following treatment, precautionary
measures may be taken to cleanse the treatment site.
Integrated CTAA/ESA Apparatus
[0075] There are several embodiments suitable for achieving
spatially and temporally controlled TAA relative to application of
electrical signals. A preferred embodiment providing spatial and
temporal control is an apparatus wherein therapeutic agent
administration and ESA are accomplished by means of an integrated
unit. The integrated unit may utilize administration means such as
an automatic injection apparatus (FIG. 2) or a jet injector
apparatus (FIG. 3) as the mode of CTAA, with
electroporation-inducing electrical fields as the mode of ESA. Such
an embodiment does not limit this invention of combined employment
of CTAA and electroporation to an integrated unit, or by said
means. However, integration of such an apparatus provides improved
temporal and spatial control that may not be as accurately achieved
with application of individual CTAA and electroporation units.
Embodiments
[0076] The appropriate temporal and spatial generation of an
electroporation-inducing electrical field with respect to the
timing and location of the therapeutic agent administration is
critical for achievement of consistent and reproducible therapeutic
effects. For instance, if the operator administers a therapeutic
agent with one apparatus, and then employs another apparatus for
establishment of an electroporation-inducing electrical field,
there may be variability in the relative temporal and spatial
applications of CTAA and electroporation. Such inter-patient
variability, due to inter-operator variability, can result in
highly undesirable therapeutic inconsistencies. In the practice of
the proposed integrated unit, operator training and variability are
significantly reduced, since the spatial and temporal relationship
of the CTAA and electroporation are controlled through the use of
an integrated application system and control means rather than the
operator. Furthermore, operator error by inconsistent and
inaccurate temporal and spatial establishment of the
electroporation-inducing electrical field relative to the
therapeutic agent administration may be minimized, enabling
reproducible and consistent therapeutic efficacy and dosing.
[0077] In all embodiments, administration of the therapeutic agent
is performed in a spatially and temporally controlled fashion
relative to ESA. Accordingly, spatial control and temporal control
are both addressed below as separate aspects. Though addressed
separately, these aspects may be combined in all such embodiments
to form an integrated application unit providing both spatial and
temporal control over administration of the therapeutic agent. The
particular combination of embodiments employed is dictated by the
specific indication.
Embodiments providing Temporal Control
[0078] In the combination of therapeutic agent application and
electroporation, the need for temporal control is twofold: 1) the
ability to administer the therapeutic agent at a controlled rate,
and 2) the ability to control the sequence and timing of TAA and
electroporation application. In the present invention, the former
issue is addressed by the use of an automated injection apparatus,
and the latter is addressed by integrating this automated injection
apparatus with an appropriate means for the application of
electroporation.
[0079] The rate of therapeutic agent administration into the tissue
is largely controlled by the design of the administration
apparatus. Two common administration methods that provide suitable
control over the rate of agent administration are automatic
injection apparatuses 10 and jet injector apparatuses 100. For both
administration methods, an energy source 30 is required to transfer
the therapeutic agent from a suitable reservoir 28 in the apparatus
through an orifice 14, 104 and into a target region of tissue at a
controlled rate. Suitable sources of energy for automatic injection
apparatuses and jet injectors include springs, compressed gas, and
electromechanical means. The rate of administration may be
controlled by regulation of several parameters, including the
energy source (e.g. spring constant, gas pressure, voltage, or
current), needle diameter, orifice diameter, and agent viscosity.
The parameters may be selected by the operator prior to
administration to set the desired rate. However, once
administration is initiated, the rate is operator-independent, and
the agent is transferred at a predetermined rate.
[0080] In the practice of the present invention, an integrated unit
is applied to the therapy recipient, allowing the desired sequence
and timing of CTAA and electroporation to be achieved in a
controlled and reliable fashion without undesirable time delays
and/or multiple apparatus placements. For example, one treatment
protocol calls for the administration of plasmid DNA encoding for a
therapeutic protein, followed by generation of an
electroporation-inducing electrical field, and then followed by
administration of dexamethasone. In the absence of the present
invention, there would be three different apparatus placements,
with an unavoidable time interval in between the operator's
placement and activation of each apparatus. This complexity
increases the probability that inter-patient variability would
arise from inconsistent temporal application of each apparatus by
individual operators who are likely to have substantially different
skill levels. This complexity and variability is compounded in the
case where multiple application sites are necessary to get adequate
dispersal of the agent to a treatment region within the target
tissue. Using the described invention, however, only a single
apparatus is required, enabling any desired sequence of CTAA,
electroporation, and additional procedures to be applied with
minimal spatial and temporal variability and limitations. This
feature is critical for agents that must reach the interior of the
target cells to maintain efficacy. The treatment may not be
consistently and reliably accomplished with multiple units, where
temporal limitations and injection rate variability may be present
in the treatment regimen. For example, when plasmid DNA is exposed
after in vivo administration to the extracellular environment,
physiological enzymes (DNases) break it down. Since the exact rate
of enzymatic activity is dependent on the specific patient,
minimizing the time interval between CTAA and electroporation
allows more accurate control over the treatment dosage. In the in
vivo environment, viability must be maintained by expeditious entry
of the therapeutic agent to the interior of the target cells, and
this may not be as consistently and reliably achieved with multiple
units as it may be with an integrated unit, with which time lags
are not a significant limitation and enzymatic activity is reduced
as a source of variability.
Embodiments providing Spatial Control
[0081] There are several embodiments suitable for achieving
spatially controlled therapeutic agent administration. One
embodiment suitable for spatially controlled therapeutic agent
administration is a template 52, as depicted in FIGS. 5A-D,
containing a single (FIG. 5A) or a plurality (FIGS. 5B-D) of ports
54 designed to accommodate injection orifices characteristic of a
jet injector or automatic injection apparatus at a fixed location
relative to electrodes 56 suitable for generation of
electroporation-inducing electrical fields. Additionally, the use
of ports 54 provides improved angular and depth control over
administration of the therapeutic agent. The template 52 may
contain a single or plurality of port interlocks for administration
apparatus stabilization, through which any combination of automatic
injection apparatuses or jet injectors may be connected and
employed in a spatially controlled fashion.
[0082] A preferred embodiment of the invention that provides
spatial and temporal control in the delivery of therapeutic agents
is an apparatus wherein CTAA and ESA are accomplished by means of
an integrated unit. The integrated unit may utilize administration
methods such as an automatic injection apparatus or a jet injector
as the mode of CTAA, with electroporation-inducing electrical
fields as the preferred mode of ESA. There may also be indications
for which any combination of single or multiple automatic injection
apparatuses and jet injectors are beneficial. For instance, the
TriGrid.TM. electrode array allows for virtually all target tissue
volumes and shapes to be treated with a single placement of the
array. An apparatus with multiple agent administration means would
then allow for reproducibly co-localized CTAA and electroporation
to a wide variety of target tissues with a single placement of the
integrated unit. The number of administration means implemented
with respect to the number of Unit TriGrid.TM. arrays may depend on
various treatment parameters, including the nature of the agent to
be delivered, the desired dosing, the type and location of the
target tissue, and the volume to be treated.
[0083] In the practice of the invention utilizing such embodiments,
the integrated unit is placed in the desired location, the
administration apparatus is employed to administer the therapeutic
agent, and the electrode array of electrodes is activated in the
target tissue, all without spatial relocation of the integrated
unit. Desirably, the electrode array can be provided with the means
to adjust the spatial relationship to the orifice, for example, by
providing retractable electrodes. In such an embodiment, the
electrodes would then be deployed upon command, and activated at
the appropriate time, in order to effect the EMTAD treatment. The
electroporation-inducing electrical field is thereby established,
enabling delivery of the therapeutic agent to the interior of the
target cells, and the electrode array is then retracted from the
target tissue. This single-placement apparatus minimizes spatial
variability and limitations on the sequential application of CTAA
and electroporation, while enabling highly accurate control over
spatial parameters, such as the application of CTAA relative to
electroporation. This is especially important for electroporation,
where reproducible co-localization between the therapeutic agent
and the target tissue is optimal for therapeutic agent delivery in
consistent, efficacious therapies.
[0084] In all embodiments described above, additional
distributional control is derived from combination of rate control
with a template-based apparatus, or as a component of an integrated
unit. For example, if a plurality of administration apparatuses is
used, then the spatial and temporal relationship between location
and timing of injections is readily controlled, thereby providing a
more consistent, rapid, and homogeneous distribution of the
therapeutic agent.
Description of an Exemplary Integrated Unit Embodiment
[0085] As depicted in FIGS. 2, 3, 6 and 7, the integrated unit may
use an automatic injection apparatus 10, jet injector 100, or any
combination thereof as the mode of CTAA. For certain indications,
an automatic injection apparatus 10 may be the preferred mode of
CTAA. The automatic injection apparatus may use standard syringes
and needles, fixed or non-fixed. A disposable, self-destructible,
and/or pre-filled needle-syringe unit 18 may be preferable for
certain indications. The needle should be positioned within a
penetration-depth controlling housing 16, thereby preventing
accidental needle stick. For added safety, the automatic injection
apparatus may provide retraction of the needle once insertion and
injection has been completed. Accidental discharge prevention means
may also be desirable. For other indications, a needleless or
mini-needle jet injector 100 may be the preferred mode of CTAA. A
disposable, self-destructible, and/or pre-filled vial 110
containing the agent may be preferable for certain indications. If
the jet injector contains a mini-needle, as may be the case for
transcutaneous penetration, the mini-needle should be positioned to
prevent accidental needle stick. Likewise, the jet injector may
provide retraction of the mini-needle once insertion and injection
has been completed. It may also be desirable to have accidental
discharge prevention means. For all administration apparatuses
containing needles and mini-needles, it may be desirable to have
the deployed or retracted state of said needles and mini-needles
displayed to the operator.
[0086] The integrated unit may use the TriGrid.TM. array as the
mode of implementing ESA, with elongate electrodes 56 disposed
according to the tissue shape and volume to be treated. In one
embodiment of the invention, an integrated apparatus 200, shown in
FIGS. 6 and 7, includes an array of electrodes 202 contained within
a separable, and optionally disposable, sub-assembly 204 that can
be easily attached to and removed from the main unit 206, allowing
for controlled-usage and disposable electrodes. As described above,
certain embodiments of the invention employ retractable electrodes
208, as it is preferable if the electrodes can be contained within
the apparatus 200 prior to their deployment into the target tissue.
In cases of transcutaneous application, retractable electrodes
would allow for improved operator safety, reduced risk of a loss in
electrode sterility prior to insertion and mitigation of any
belonephobia for the patient. Control over movement of such
electrodes may be provided by spring, compressed gas, or other
appropriate energy source 210 in conjunction with a drive mechanism
212 to extend the electrodes 208 through port 228 and into the
patient. The electrodes 208 may be actuated individually or as a
unit, and preferably, the deployed or retracted state of the
electrodes is displayed, either individually or as a unit, to the
operator. As with automatic and jet injection apparatuses, the use
of retractable needle-type electrodes 208 may reduce belonephobia
experienced by the therapy recipient, while providing the operator
with increased safety to blood borne pathogens and other
needle-stick related injury.
[0087] Electrical continuity is necessary between the desirably
active electrodes and the electrical signal generator. Therefore,
in embodiments where the electrode array is detachable, a
continuous and reliable electrical connection 214 should be readily
achieved between the electrodes 208 within the array 202 and the
apparatus 200. The invention also includes an electrical signal
generating means 216 in conductive communication with the apparatus
200. The nature of the electrical signal generating means 216 will
depend on the desired application. In some embodiments, the
electrical signal generating means 216 can be located 226 within
the integrated apparatus 200. Desirably, in such an embodiment the
connections necessary to maintain electrical continuity between the
electrodes and the electrical signal generator are housed internal
to the apparatus. In the case of external electrical signal
generating means 216, as depicted in FIG. 7, a cable 218 between
the generator 216 and the apparatus 200 is provided with a suitable
connector 220 located on the apparatus 200 in a manner to minimize
interference with operator use. As electrodes 208 may be retracted
or deployed, conductive housing 222 is provided for electrical
connection between deployed electrodes and the electrical signal
generator 216. Conductivity may also be accomplished by connection
220 through the electrode drive mechanism 212 and/or energy source
210.
[0088] Selection of electrode parameters is an important component
of electroporation therapy. Electrode parameters include diameter,
tip profile, length, conductivity, and materials. The electrodes
may be hollow, allowing for the administration of anesthetics or
other agents. The electrodes may also be coated with anesthetics
and/or lubricious agents for pain mitigation and ease of insertion.
The electrode parameter selection is dictated by several treatment
factors, including properties of the target tissue, tissue volume
to be treated, and charge injection/current densities at the
electrode-tissue interface. For example, in the transcutaneous
application of electroporation, trocar tip 58 (polyhedron with
three faces) electrodes with a nominal diameter of 0.005'' to
0.05'' are desirable. The inter-electrode spacing 60 and
penetration depth define the volume of tissue to be treated. For
electroporation in healthy tissues, it is often desirable that the
electrodes have a sufficiently inert surface material 62 which is
electrochemically stable and will not exhibit substantial
oxidation-reduction reactions with the interstitial environment
when exposed to high charge injections that may occur as a result
of ESA. Such surfaces may be platinum, platinum-iridium, iridium,
iridium-oxide, gold, and titanium nitride. Depending upon the
material chosen, it may be desirable for cost and structural
reasons to deposit these inert metals onto the surface of a base
metal. Appropriate base metals include, but are not limited to
titanium, tungsten, and MP35N.
[0089] The process of deposition for the desired electrochemically
stable coating may consist of chemical or physical vapor
deposition, creating coatings on the order of tenths to hundreds of
microns. The level of charge injection and irreversible
oxidation-reduction reactions should be considered when choosing a
sufficiently inert material and deposition thickness.
[0090] Potential for substantial oxidation-reduction reactions with
the interstitial environment only exists at the electrodes where a
positive potential is applied. Therefore, for applications that do
not require sequencing of electrode polarity, it may be desirable
for cost and structural reasons to utilize electrochemically inert
materials or coatings only on the these pulse positive
electrodes.
[0091] In order to target the electroporation-inducing electrical
fields to a specified region, including elimination of
non-homogeneous electrical fields from the electrode tips 64,
dielectric coatings 66 such as Polytetrafluoroethylene (PTFE),
Parylene, and Silicon Carbide may be deposited onto the electrode
at thicknesses of tenths to hundreds of microns. The pinhole size
and dielectric strength of such coatings should be considered when
choosing an appropriate dielectric material and thickness.
[0092] A further aspect of the invention provides a system wherein
the sequential timing and functions of the integrated
CTAA-electroporation unit are controllable. This may provide, for
example, presettable procedure parameters, procedure automation,
and/or closed loop systemic control. The control system 224 of the
integrated unit may regulate parameters pertaining individually to
CTAA and electroporation, and collectively to their integrated
function. In certain embodiments, the control system may regulate
the effective administration and dosing of therapeutic agents by
adjustment of CTAA and electroporation parameters. Other treatment
parameters to be controlled include application of a local
anesthetic, placement and removal of retractable electrodes,
administration of additional therapeutics, and the timing and
duration of each step of the procedure.
[0093] In certain embodiments, the control system and means for
electrical signal generation are incorporated into a portable or
handheld unit for use with the integrated CTAA-electroporation
apparatus. For portability, a spring or compressed gas may be used
as a means of therapeutic agent propulsion, having multiple
settings for operator-selectable rate control over agent
administration. If a spring is used, then the loaded and unloaded
state of the spring should be displayed to the operator. If
compressed gas is used, a qualitative or quantitative pressure
level should be displayed to the operator. In this embodiment the
unit may be powered by battery, capacitor bank, or pulse forming
network that is energized by use of a portable station, solar
cells, or other electrical sources.
Description of a Specific Integrated Unit Embodiment for
Transcutaneous Applications.
[0094] An exemplary specific embodiment of an integrated unit for
transcutaneous applications is illustrated in FIGS. 8, 9, 10, 11
and 12. This embodiment incorporates an automatic injection
apparatus as the mode of CTAA. Additionally, this embodiment
incorporates an automatic mechanism to introduce the electrodes
into the patient.
[0095] As depicted in the Figures, the apparatus 300 of this
embodiment consists of a main unit 306 and a separable and
optionally disposable (single use) sub-assembly 304 that is easily
attached and separated from the main unit 306. This embodiment is
designed so that only the sub-assembly 304 comes into contact with
the patient when the apparatus is in use. This feature allows for a
reduced risk of cross-contamination of bodily fluids between
patients. Additionally it can improve operator safety by reducing
the need to clean and sterilize the main unit 306.
[0096] The sub-assembly 304 may be attached to the main unit 306
with a twist lock, including a receiving channel 314 as shown in
FIGS. 8A and 9A and a complementary detent or projection (not
shown) in the housing of the main unit 306. Alternatively, a
thread, a snap fit or any convenient securing means may also be
employed. A syringe-needle unit 18 and an array of retractable
electrodes 308 are contained within the sub-assembly 304 as
depicted in FIG. 9B. The needle 12 of the syringe-needle unit 18
and the electrodes 308 are maintained in a retracted state within
the sub-assembly housing 316 until the treatment is initiated, the
apparatus is activated and the needle 12 and electrodes 308 are
introduced into the patient. The provision of a retracted needle
and electrodes in the present apparatus improves operator safety,
reduces the risk of contaminating the needle and/or electrodes and
helps to mitigate any patient blenophobia. In addition, subassembly
304 may incorporate a removable seal or cover over the electrode
and needle ports 328 to prevent accidental contamination of
electrode array 50 or needle 12 prior to application of the
apparatus 300 to the patient.
[0097] The electrodes 308 and the syringe-needle unit 18 are both
attached to a hub 302 within the sub-assembly 304. The hub 302
maintains a specified spatial relationship, designed according to
various treatment parameters and objectives, between the needle
orifice 14 and the array 50 of electrodes 308. The electrodes 308
may be attached to the hub 302 with an adhesive bond, an
interference fit or they may be insert-molded into the hub 302. The
syringe-needle unit 18 may be attached to the hub 302 with a snap
fit or a light interference fit, both of which allow the
syringe-needle unit 18 to be easily removed and reattached to the
sub-assembly 304 so that it may be conveniently loaded with a
therapeutic agent. In some cases the syringe-needle unit 18 may
come pre-loaded with a therapeutic agent.
[0098] The hub 302 is designed to slide axially within the housing
316 to extend needle 12 and electrodes 308 through their separate
ports 328 and into the patient. A spring 332 maintains the hub 302
in a position so that the needle 12 and the electrodes 308 are
retracted within the housing 316 until the treatment is initiated
and the needle 12 and electrodes 308 are introduced into the
patient. In addition to means to retract the needle 12 and array 50
of electrodes 308 within the sub-assembly 304 housing 316, the
sub-assembly 304 contains an extending shield 326. As depicted in
FIG. 11D, the shield 326 extends over the extended needle 12 and
electrode array 50 after the treatment is complete and the needle
12 and electrode array 50 have been removed from the patient. A
shield can reduce the risk of post treatment needle stick accidents
and thereby reduce the risk of transfer of blood borne pathogens. A
spring 327 enclosed within the sub-assembly 304 acts upon the
shield 326 and allows the shield 326 to retract when the needle 12
and electrode array 50 are inserted into the patient and extends
the shield 326 to cover the needle 12 and electrode array 50 when
they are removed from the patient. The spring 327 should have
adequate force to prevent the shield 326 from being accidentally
retracted. It may also be advantageous for the shield 326 to lock
in the extended position once the treatment has been completed,
thereby eliminating the risk of accidental post treatment
retraction of the shield 326.
[0099] A specific embodiment of the main unit 306 is illustrated in
FIGS. 8,10, 11 and 12. This specific embodiment incorporates
mechanisms to insert the needle 12 and the electrode array 50 into
the patient and to transfer the therapeutic agent from the
syringe-needle unit 18 to the patient at a controlled rate. As
depicted in FIGS. 11A-B, drive mechanism 312 engages with the hub
302 of the sub-assembly 304 to extend the needle 12 and electrode
array 50 into the patient. A compression spring 310 is utilized as
the energy source to advance the drive mechanism 312. A solenoid
334 engages the drive mechanism 312 and maintains the spring 310 in
a primed state. When the solenoid 334 is energized the solenoid
shaft 336 retracts and releases the drive mechanism. As illustrated
in FIG. 11C, a second drive mechanism 324 engages with the plunger
20 of the syringe-needle unit 18 to transfer the therapeutic agent
from the syringe reservoir 28 through the needle 12 and into the
patient. A compression spring 330 is utilized as the energy source
to advance the drive mechanism 324 and plunger 20. A second
solenoid 338 engages with the drive mechanism 324 and maintains the
spring 330 in a primed state. An electric signal is applied to the
solenoid 338 to retract the solenoid shaft 340 and release the
drive mechanism 324.
[0100] This specific embodiment of the main unit 306 is connected
to a control system and electrical signal generator through a cable
318 and a connector 320. The control system regulates the sequence
and timing of needle and electrode insertion into the patient, CTAA
and ESA. An operator activation trigger 22 on the main unit 306
sends a signal to the control system to initiate the treatment
sequence. It may be desirable to include a safety mechanism with
the trigger 22 to prevent accidental actuation of the trigger 22
and treatment sequence. Electrical continuity between the signal
generator and the retractable electrodes 308 is achieved through a
conductive band 322 that is connected to the signal generator
through the cable 318 and connector 320. As illustrated in FIG. 9,
the electrodes 308 are formed so they protrude beyond the profile
of the sub-assembly 304. When the electrodes 308 are advanced the
protruding portion makes contact with the conductive band 322 in
the main unit. FIG. 12 depicts the contact between the electrodes
308 and the conductive band 322. Depending upon the application
each electrode 308 can be positioned axially within the
sub-assembly so as to contact an individual conductive band 322 or
groups of electrodes 308 may contact specific conductive bands 322.
To limit any signal loss the electrode 308 may be formed to
maximize the contact area with the conductive band 322.
Alternatively, conductive pads or other conductive means can be
employed in place of conductive bands 322.
EXPERIMENTAL RESULTS
Example 1
Study of Electrochemically Stable Electrode Materials
[0101] Experiments are carried out to evaluate the relative
electrochemical stability and biocompatibility of electrode
materials and/or coatings. Since the practice of the present
invention requires acute implantation of electrodes and the
application of electrical fields in tissue, electrochemically
stable electrodes or electrode coatings are desirable. Electrodes
comprised of reactive metal species can lead to oxidation/reduction
reactions at the electrode tissue interface. These reactions can
cause several potentially undesirable effects including gas bubble
formation, electrode dissolution and electroplating. In addition to
negatively affecting the ESA, these reactions may represent a
significant safety concern when applied to healthy tissue.
[0102] In these experiments a standard array configuration of
electrodes is immersed in normal saline. Each array is composed of
electrodes of a specific material and/or coating composition. A
standard electroporation pulse protocol is then applied to the
electrode array. To assess relative electrochemical stability of
the electrodes each resulting saline extract is analyzed with
Inductively Coupled Plasma Spectroscopy (ICPS) to determine the
presence and concentration of any metallic elements in solution.
The extract is also evaluated for cytotoxicity (ISO Agarose Overlay
method) to assess the biocompatibility of the electrodes.
[0103] A control extract is prepared in which stainless steel
electrodes are immersed but no electrical signals are applied. ICPS
results show no trace of metallic elements in the control extract.
Additionally the cytotoxicity test produces a non-toxic result.
[0104] Stainless steel is thought to be a reactive metal so a
positive control extract is prepared with an array of stainless
steel electrodes. This stainless steel electrode extract contains
measurable quantities of all the metallic elements that constitute
stainless steel (chromium, iron, manganese nickel and silicon).
This extract also yields a toxic result in the cytotoxicity
test.
[0105] To evaluate platinum-iridium (PtIr) as an electrode
material, an array of PtIr electrodes is used to prepare another
extract. ICPS analysis of the Pt--Ir saline extract shows no
measurable trace of metallic elements from the electrodes.
Additionally in vitro cytotoxicity testing of the same saline
extract shows no evidence of toxicity.
[0106] To evaluate titanium nitride (TiN) as a coating for
stainless steel electrodes, an additional extract is prepared using
an array of stainless steel electrodes coated with TiN. ICPS
analysis of the TiN saline extract shows only titanium in solution.
None of the stainless steel elements are detected in the extract
solution. Moreover, the cytotoxicity testing of the TiN saline
extract produces a non-toxic result.
[0107] To evaluate the effect of coating only the electrodes where
a positive potential is applied (positive electrodes), two
electrode arrays are prepared. The first array (TiN-positive array)
consists of TiN coated stainless steel positive electrodes and
non-coated stainless steel negative electrodes. The second array
(TiN-negative array) consists of non-coated stainless steel
positive electrodes and TiN coated stainless steel negative
electrodes. A saline extract is prepared for each array. ICPS
analysis of the TiN-positive array extract shows only titanium in
solutions and no measurable quantities of stainless steel elements.
Cytotoxicity testing of the TiN-positive array extract produces a
non-toxic result. In contrast to the TiN-positive array extract,
the TiN-negative array extract shows measurable quantities of all
the stainless steel elements (chromium, iron, manganese nickel and
silicon) during ICPS analysis. Additionally the TiN-negative array
extract yields a toxic result in in vitro cytotoxicity testing.
Example 2
In Vivo Delivery of Erythropoietin Encoding Plasmid DNA into
Skeletal Muscle
[0108] In the experimental disclosure which follows, all weights
are given in grams (g), milligrams (mg), micrograms (.mu.g),
nanograms (ng), or picograms (pg), all amounts are given in moles
(mol), millimoles (mmol), micromoles (.mu.mol), nanomoles (nmol),
picomoles (pmol), or femtomoles (finol), all concentrations are
given as percent by volume (%), proportion by volume (v:v), molar
(M), millimolar (mM), micromolar (.mu.M), nanomolar (nM), picomolar
(pM), femtomolar (fM), or normal (N), all volumes are given in
liters (L), milliliters (mL), microliters (.mu.L), or cubic
centimeters (cc), and linear measurements are given in millimeters
(mm), micrometers (m), or nanometers (nm), unless otherwise
indicated. The following examples demonstrate the practice of the
present invention for the in vivo application of electroporation to
enhance delivery of therapeutic agents.
[0109] In vivo studies are performed to evaluate the use of the
present invention in the delivery of a plasmid encoding the rabbit
erythropoietin (EPO) gene into rabbit skeletal muscle. Effective
transfer of the gene results in endogenous production and systemic
distribution of the rabbit erythropoietin protein.
[0110] Tests are conducted using New Zealand White rabbits between
2.5 and 4 kg body mass. Animals are anesthetized using a cocktail
of ketamine/xylazine. Once an appropriate level of anesthesia is
achieved as assessed by toe pinch, the fur above the right and left
quadriceps muscles is shaved. The skin in the shaved region is
prepped aseptically.
[0111] A TriGrid.TM. electrode array consisting of four electrodes
arranged in two interlocking equilateral triangles is utilized for
all experiments. The intra-electrode distance for this array is 7
mm. The length of the electrodes is 2.0 cm. The diameter of the
electrodes is 0.5 mm.
[0112] The plasmid DNA delivered in all studies incorporates the
rabbit erythropoietin gene under the control of the CMV promoter
with an immediate early enhancer. A standard dose of 1.5 mg plasmid
DNA in a volume of 0.5 cc is loaded into a standard 1.0 cc syringe
with a 23-gauge 1-inch hypodermic needle. The plasmid DNA dose is
administered bilaterally into the right and left quadriceps muscles
(total dose 3.0 mg) for all experiments.
[0113] In the first experimental group (Group 1), the procedure is
initiated with the implantation of the TriGrid.TM. electrode array
into the right rectis femoris muscle. The syringe is then implanted
by a technician through a fixed port in the electrode array to a
pre-determined depth (19 mm). Once the needle/syringe is in
position, the intramuscular injection is administered manually by
the technician at a standardized rate (0.5 cc/5 seconds). Twenty
seconds after completion of the injection, a series of four
electrical pulses (200 Volts amplitude, 10 ms duration, 2 Hz
frequency) are delivered to the muscle through the implanted
electrode array. The electrode array and syringe are removed and
the procedure is repeated for the left rectis femoris muscle.
[0114] In the second experimental group (Group 2), the standard 1.0
cc syringe is loaded into an integrated applicator unit consistent
with the present invention. The procedure is initiated with the
application of the integrated unit to the skin above the right
rectis femoris muscle, implanting the electrodes into the target
site. Once the electrodes are implanted, the technician deactivates
the safety interlock and actuates the trigger mechanism. Actuation
of the trigger mechanism leads to a controlled insertion of the
hypodermic needle at a pre-determined location and depth followed
by intramuscular administration of the plasmid DNA dose at a
controlled, user independent rate of injection (0.5 cc/5 seconds).
Twenty seconds after completion of the injection, a series of four
electrical pulses (200 Volts amplitude, 10 ms duration, 2 Hz
frequency) are delivered to the muscle through the implanted
electrode array. The electrode array and syringe are removed and
the procedure is repeated for the left rectis femoris muscle.
[0115] Six days after the procedure, a serum sample is obtained
from all animals in Groups 1 and 2. The serum sample is analyzed
using an ELISA assay for human erythropoietin (Research
Diagnostics, Flanders, N.J.). ELISA analysis of the serum samples
from each animal provides a quantitative assessment of the amount
of rabbit EPO protein present in the sample.
TABLE-US-00001 TABLE 1 EP mediated Intramuscular EPO Gene Delivery
in Rabbits Serum EPO Levels Group n (U/mL) % Standard Deviation 1
12 40.5 51% 2 12 44.6 24%
[0116] It is apparent from the results that animals in Group 2
exhibit a significantly lower degree of variability than the
animals in Group 1. This suggests that use of the present invention
enables more consistent and reproducible transfer of nucleic acids
into skeletal muscle.
[0117] All patents and patent applications cited in this
specification are hereby incorporated by reference as if they had
been specifically and individually indicated to be incorporated by
reference.
[0118] Although the foregoing invention has been described in some
detail by way of illustration and Example for purposes of clarity
and understanding, it will be apparent to those of ordinary skill
in the art in light of the disclosure that certain changes and
modifications may be made thereto without departing from the spirit
or scope of the appended claims.
* * * * *